Astrazeneca Pharma India Ltd

This is to inform that AstraZeneca Pharma India Limited has received permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation - Additional Indication) from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.Through this approval Dapagliflozin Tablets 10 mg is indicated for the treatment of heart failure in adults.The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10 mg in India for the specified indication subject to the receipt of related statutory approvals and licenses.